DiaSys Corporation Announces Three-Year Renewal of Exclusive Distribution Agreement in China.Business Editors/Health/Medical Writers WATERBURY, Conn.--(BUSINESS WIRE)--Sept. 22, 2003 DiaSys Corporation (AMEX AMEX See: American Stock Exchange :DYX DYX Dyslexia ), a global healthcare products company, today announced that it has renewed the exclusive distribution agreement in China for an additional three-year period with Hua-Sin Science Co., Ltd., a leading medical diagnostic distributor and manufacturer in China. Hua-Sin began promoting, selling and servicing DiaSys's urinalysis and parasitology Parasitology The scientific study of parasites and of parasitism. Parasitism is a subdivision of symbiosis and is defined as an intimate association between an organism (parasite) and another, larger species of organism (host) upon which the parasite is workstations and consumable products in China in 1999. DiaSys Corporation is also working with Hua-Sin Science Co., Ltd., to develop and market a new series of Parasitology and Urinalysis workstations for sale to over 60,000 hospitals in China in addition to their territory in Pacific Asia. Commenting on the news, Marshall Witzel, DiaSys' CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. said, "We are very pleased with the support for our products that Hua Sin continues to market. We are looking forward to strengthening and broadening our relationship with Hua Sin, the leading medical diagnostic distributor and manufacturer in China." Mrs. Liu Guangsheng, Director of Sales and Marketing for Hua Sin Science Co., Ltd., said, "Our steady relationship will bring a mutual and huge business opportunity. Hua Sin will keep on introducing the advanced products and technology, and providing the best service to all the customers in this area." DiaSys Corporation designs, develops, manufactures and distributes proprietary medical laboratory equipment, consumables and test kits to healthcare and veterinary diagnostic laboratories worldwide. Headquartered in Waterbury, CT, the Company operates in Europe through its wholly owned subsidiary Wholly Owned Subsidiary A subsidiary whose parent company owns 100% of its common stock. Notes: In other words, the parent company owns the company outright and there are no minority owners. based in Wokingham, England and in Pacific Asia through its strategic business partner located in Guangzhou, China. DiaSys, Parasep and Urisep are registered trademarks of DiaSys Corporation. This press release contains forward looking-statements within the meaning of and made pursuant to, the safe harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. provisions of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. The forward looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results performance or achievements of the Company or events, or timing of events, relating to relating to relate prep → concernant relating to relate prep → bezüglich +gen, mit Bezug auf +acc the Company to materially differ from those expressed or implied by such forward looking statements. DiaSys refers interested parties to its most recent Annual Report on Form 10-KSB and other SEC filings for a complete description of, and discussions about, the Company. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion